肿瘤药学2019，Vol.9Issue(3)：415-418,4.DOI:10.3969/j.issn.2095-1264.2019.03.13
阿比特龙与多西他赛治疗去势抵抗性前列腺癌的对比研究
Therapeutic Effects of Abiraterone vs. Docetaxel on Castration-Resistant Prostate Cancer
魏军 1董锐 2刘飞 2王宁华 2刘钰 2程帆1
作者信息
- 1. 武汉大学人民医院泌尿外科,湖北 武汉,430060
- 2. 武汉市汉阳医院,湖北 武汉,430050
- 折叠
摘要
Abstract
Objective To investigate the efficacy and adverse reactions of abiraterone acetate vs. docetaxel on castration-resistant pros-tate cancer. Methods Between August 2016 and August 2017, 60 patients with castration-resistant prostate cancer were treated in our hos-pital. All patients failed to receive androgen deprivation therapy and no chemotherapy and radiotherapy before. The sixty patients were ran-domly divided into abiraterone group (n=30) and docetaxel group (n=30). Patients in the abiraterone group were treated with abiraterone and prednisone, and those in the docetaxel group were treated with docetaxel and prednisone. The clinical efficacy and adverse reactions of the two groups were observed. The serum prostate special antigen (PSA) levels were measured. Results The one-year disease progression rates of the abiraterone group and docetaxel group were 46.67% and 80% respectively, and the adverse reaction rates were 26.67% and 76.67%, respectively (P<0.05). Before treatment, the serum PSA levels were high in both groups, and there was no difference between the two groups (P>0.05). The levels of neutrophils of the two groups were in the normal range and there was no significant difference in neutrophils levels (P>0.05). After treatment, the level of PSA in the serum of the two groups decreased significantly. What’s more, the PSA level was lower in the abiraterone group than in the docetaxel group (P<0.05). The serum neutrophils level declined significantly in both groups, but it de-clined much greater and below the normal range in docetaxel group (P<0.05). Conclusion Compared with docetaxel treatment, abiraterone treatment has better disease control rate and survival benefit, and the adverse reactions are greatly reduced. It is worthy of further clinical research and application.关键词
阿比特龙/多西他赛/去势抵抗性前列腺癌Key words
Abiraterone/Docetaxel/Castration-resistant prostate cancer分类
医药卫生引用本文复制引用
魏军,董锐,刘飞,王宁华,刘钰,程帆..阿比特龙与多西他赛治疗去势抵抗性前列腺癌的对比研究[J].肿瘤药学,2019,9(3):415-418,4.
